MSP–RON signalling in cancer: pathogenesis and therapeutic potential

Hang-Ping Yao,Yong-Qing Zhou,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1038/nrc3545

IF: 78.5

2013-01-01

Nature Reviews Cancer

Abstract:Key Points Macrophage-stimulating protein (MSP; also known as MST1 and hepatocye growth factor-like (HGFL)), is a serum-derived growth factor that activates the RON receptor tyrosine kinase. RON signalling is essential for the survival of embryos during the peri-implantation period. Cancer cells use MSP–RON signalling for survival, migration, angiogenesis and chemoresistance, which has pathogenic implications. Crystal structure analyses have shown that a central cleft harbouring three amino acid residues in the putative catalytic site of the MSP β-chain interacts with an interface created by two RON semaphorin (SEMA) domains. This supports a model in which one MSP molecule binds two RON molecules to cause receptor dimerization and activation. Aberrant RON activation, which is induced by overexpression of protein and the generation of oncogenic isoforms and is indicated by the persistent activation of multi-intracellular signalling cascades, occurs in various types of cancers. RON signalling is also necessary for cancer cell growth and survival. These features render RON as a drug target for cancer therapy. MSP–RON signalling activates two classical signalling pathways, RAS–ERK and PI3K–AKT, both of which interact with various other pathways to create a complex signalling network. RON also crosstalks with other receptor tyrosine kinases and viral oncoproteins. Such intricate interactions highlight the importance of RON signalling in cancer pathogenesis. Overexpression of RON in primary tumours such as colon and breast cancer is predictive of patient survival and correlates with clinical and pathological parameters. Studies from mouse xenograft models have revealed that inhibition of RON by tyrosine kinase inhibitors and monoclonal antibodies blocks tumour growth. However, combinations with chemoagents achieve maximum therapeutic benefit. The tyrosine kinase inhibitor BMS-777607 and the RON-specific antibody narnatumab are currently in Phase I clinical trials.